Phase II Study of RAD001 [everolimus] Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell).

Trial Profile

Phase II Study of RAD001 [everolimus] Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Everolimus; Octreotide
  • Indications Neuroendocrine carcinoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 06 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top